18F-FDG PET/CT Detection of Extensive Pleural Metastasis in Rare Malignancy Thymoma
PDF
Cite
Share
Request
Interesting Image
VOLUME: 34 ISSUE: 3
P: 252 - 254
October 2025

18F-FDG PET/CT Detection of Extensive Pleural Metastasis in Rare Malignancy Thymoma

Mol Imaging Radionucl Ther 2025;34(3):252-254
1. University of Health Sciences Türkiye, Elazığ Fethi Sekin City Hospital, Clinic of Nuclear Medicine, Elazığ, Türkiye
2. Ankara Bilkent City Hospital, Clinic of Nuclear Medicine, Ankara, Türkiye
No information available.
No information available
Received Date: 09.01.2025
Accepted Date: 29.06.2025
Online Date: 08.10.2025
Publish Date: 08.10.2025
PDF
Cite
Share
Request

Abstract

The majority of metastatic pleural lesions are caused by malignancies such as bronchogenic carcinoma (40%), breast cancer (20%), lymphoma (10%), and ovarian or gastric carcinomas (5%). However, pleural metastases from thymoma are extremely rare. In this report, we present the 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) imaging findings of a patient with thymoma and extensive pleural metastases. Although biopsy remains the gold standard for diagnosis, it is important to consider high grade thymoma in the differential diagnosis, as extensive pleural involvement observed on 18F-FDG PET/CT imaging can mimic both primary and metastatic pleural malignancies. Recognizing this possibility can assist in more accurate interpretation of imaging findings.

Keywords:
Thymoma, pleura, metastasis, 18FDG, PET/CT

Ethics

Informed Consent: The patient consent was obtained.

Authorship Contributions

Surgical and Medical Practices: M.O.K., B.O.T., Concept: M.O.K., B.O.T., Design: M.O.K., B.O.T., Data Collection or Processing: M.O.K., B.O.T., Analysis or Interpretation: M.O.K., B.O.T., Literature Search: M.O.K., B.O.T., Writing: M.O.K., B.O.T.
Conflict of Interest: No conflicts of interest were declared by the authors.
Financial Disclosure: The authors declare that this study has received no financial support.

References

1
Sandri A, Cusumano G, Lococo F, Alifano M, Granone P, Margaritora S, Cesario A, Oliaro A, Filosso P, Regnard JF, Ruffini E. Long-term results after treatment for recurrent thymoma: a multicenter analysis. J Thorac Oncol. 2014;9:1796-1804.
2
Falkson CB, Bezjak A, Darling G, Gregg R, Malthaner R, Maziak DE, Yu E, Smith CA, McNair S, Ung YC, Evans WK; Lung Cancer Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based Care. The management of thymoma: a systematic review and practice guideline. J Thorac Oncol. 2009;4:911-919.
3
Qureshi NR, Gleeson FV. Imaging of pleural disease. Clin Chest Med. 2006;27:193-213.
4
Tumapon D, Kim EE. Recurrent Thymoma with lung, pleural, and splenic metastases demonstrated on F-18 FDG PET/CT. OALib. 2023;10:1-6.
5
Gajendra S, Sahoo MK. (18)F FDG-PET/CT of malignant thymoma with pleural and diaphragmatic metastases. Lung India. 2016;33:116-177.